Tunecoat-pn: topical nerve-targeting formulations for neuropathic pain relief
TuneCoat-PN is a non-opioid, topical formulation using duloxetine-loaded nanoparticles for targeted neuropathic pain relief. It offers localized delivery, reducing adverse effects of oral medications. Validated in vitro and in vivo, it shows promise for scalable, patient-compliant pain management.
Overview
TuneCoat-PN is an innovative non-opioid topical formulation developed by Luna Labs, designed to address neuropathic pain through targeted delivery. Utilizing duloxetine-loaded lipid-based nanoparticles, this technology ensures controlled transdermal release and action specifically at inflamed peripheral nerves. By offering localized treatment, TuneCoat-PN minimizes the systemic side effects typically associated with oral serotonin-norepinephrine reuptake inhibitors (SNRIs), presenting a patient-friendly alternative that can be adapted to deliver various other pain-modulating agents.
Technical specifications
Key features:
- Utilizes duloxetine-loaded lipid-based nanoparticles for targeted, localized pain relief
- Engineered for controlled transdermal delivery to inflamed peripheral nerves
- Demonstrated in vitro association with nerve cells and in vivo efficacy in rodent models
- Franz cell assays confirm effective transdermal drug delivery
- 40% reduction in drug dosage compared to systemic routes while maintaining efficacy
Applications:
- Treatment of peripheral neuropathy and other localized pain conditions
- Platform technology adaptable for various analgesic agents
Technology readiness level
TuneCoat-PN is currently at Technology Readiness Level 5, having demonstrated in vitro and in vivo efficacy with a clear path towards clinical translation. Future validation plans include formulation refinement, safety assessments, and enhanced targeting efficiency to further its development.
About Luna Labs
Luna Labs is a product development company based in Charlottesville, Virginia, that creates specialized solutions for the defense, industrial, and healthcare sectors. The company leverages a multidisciplinary approach combining materials science, biotechnology, and systems engineering to solve complex technical challenges. By repurposing advanced technologies—such as adapting sol-gel chemistry for corrosion prevention or mimicking viral structures for drug delivery—Luna Labs develops breakthrough innovations. Their diverse portfolio includes advanced protective coatings, real-time asset monitoring systems, medical simulation training tools, and drug delivery platforms designed to improve human performance and safeguard critical infrastructure.
These technologies address significant real-world problems, such as enhancing the durability of military and aerospace assets through non-chromate corrosion control and providing medical professionals with realistic training ecosystems for hemorrhage control. By partnering with government agencies, defense contractors, and leading industrial organizations, the company focuses on advancing research from initial discovery through to commercial-scale implementation. Their commitment to innovation is evidenced by the successful deployment of their technologies in high-stakes environments and their ongoing development of platforms intended to address complex conditions like PTSD and traumatic brain injury.
Inquire about this partnering listing
Industry applications
delivered to your inbox.